Completed NA INTERVENTIONAL 2-arm NCT01921322

Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy

Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target

Sponsor: Medtronic Diabetes

Conditions Type 2 Diabetes

Interventions CGMS Gold Pump

Updated 9 times since 2017 Last updated: Jun 6, 2017 Started: Apr 30, 2013 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01921322, this NA trial focuses on Type 2 Diabetes and remains completed. Sponsored by Medtronic Diabetes, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 4 earlier versions

Feb 2020 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Feb 2020 [monthly]

Completed NA
Aug 2017 — Jun 2018 [monthly]

Completed NA

Phase: PHASE2 → NA
Jan 2017 — Aug 2017 [monthly]

Completed PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medtronic Diabetes

Data source: Medtronic Diabetes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China
• Changchun, China